Rasagiline
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Using the evidence-pack fields directly; where a field is empty/[Data Gap] I'm pulling the only sourced fact available (the mechanism note embedded in rank-4's repurposing_rationale) rather than inventing anything, and flagging the inconsistency as the pack itself does.
Rasagiline: From Parkinson's Disease to PLA2G6-associated Neurodegeneration
One-Sentence Summary
Rasagiline is a selective, irreversible MAO-B inhibitor originally used for Parkinson's disease (noted in the evidence pack's rationale text, though the drug-level MOA field itself is flagged as a data gap). The TxGNN model's top-ranked prediction is PLA2G6-associated Neurodegeneration, with a prediction score of 99.71%, but currently 0 clinical trials and 0 publications support this specific link — the connection is theoretical only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson's disease (per repurposing_rationale text; structured original_moa/original_indications fields are marked Data Gap — see DG002) |
| Predicted New Indication | PLA2G6-associated Neurodegeneration |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 (model prediction only, no trials or literature) |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured drug record (original_moa: [Data Gap]). Based on the only textual information present in this evidence pack — embedded in the rationale for a lower-ranked candidate — Rasagiline is understood to be a selective, irreversible MAO-B inhibitor that reduces dopamine breakdown and may have neuroprotective/anti-apoptotic effects, with proven efficacy in Parkinson's disease.
The top-ranked prediction, PLA2G6-associated Neurodegeneration (PLAN), is a rare genetic disorder of membrane phospholipid metabolism (including infantile neuroaxonal dystrophy and PARK14-type dystonia-parkinsonism). Some PLAN subtypes do present with a dystonia-parkinsonism phenotype, which is the only theoretical bridge to MAO-B inhibition and dopaminergic pathways. However, per the model's own rationale, this is not a classic dopamine-deficiency mechanism — PLAN is fundamentally a metabolic/structural lipid disorder, so the causal inference is weak.
Notably, a lower-ranked candidate in this pack (rank 4, "paralysis agitans, juvenile, of Hunt" — an early-onset Parkinson's-spectrum variant) shows a mechanistically much closer overlap with Rasagiline's known MAO-B action, but scored lower than PLAN and also has zero supporting evidence. This suggests the ranking here should be read as a raw model signal rather than a mechanistically validated shortlist.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
No authorization records are currently available — Rasagiline is not marketed in New Zealand under this evidence pack (total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
(Note: key_warnings, contraindications, and DDI query all returned no data (DG001 — TFDA label not yet obtained, severity: Blocking). This gap currently prevents any Stage-1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction sits at Evidence Level L5 — a model score with zero corroborating trials or literature, and the underlying mechanistic link (metabolic/lipid disorder vs. MAO-B/dopaminergic action) is explicitly described as weak in the source rationale. Compounding this, core drug-level data (MOA, package insert, safety profile) are marked as gaps, with DG001 rated Blocking for safety review.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — DG001, Blocking
- Confirmed mechanism of action via DrugBank API — DG002
- Preclinical or case-level evidence specifically linking Rasagiline to PLAN before considering any advancement past S0
- Re-evaluation of whether the mechanistically closer candidate (Hunt's juvenile paralysis agitans, rank 4) warrants separate prioritization despite its lower model score
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.